Abeta Amyloid Imaging In Neurodegenerative Disorders With A Novel 18F Radiotracer
Funder
National Health and Medical Research Council
Funding Amount
$1,084,266.00
Summary
Alzheimer's disease is the most common age-related neurodegenerative disease, and the most common cause of dementia. It is estimated that 212,000 Australians suffer from dementia and this will rise to approximately 730,000 by 2050. Currently there are no definitive diagnostic methods for AD. The research proposed in this application describes the evaluation of a new imaging radiotracer that would be suitable for widespread non-invasive diagnosis of AD.
Elucidating The Neuroprotective Region Of The Amyloid Precursor Protein (APP) Following Traumatic Brain Injury
Funder
National Health and Medical Research Council
Funding Amount
$467,556.00
Summary
Traumatic brain injury (TBI) is a leading cause of death and disability worldwide and to date there is no therapy to ameliorate this injury. There is increased production of the amyloid precursor protein (APP) following TBI and recent studies have found that APP possesses neuroprotective traits. It is the aim of the current studies to delineate the specific active neuroprotective region of APP and develop them as novel therapeutic interventions for use in TBI.
APLP2: A Neuroprotective Receptor For Acute Brain Injury
Funder
National Health and Medical Research Council
Funding Amount
$648,739.00
Summary
Traumatic brain injury (TBI) is the major cause of deaths in Australians under 45 years of age. We have shown that the amyloid precursor protein (APP) is protective in models of TBI. To understand how APP is neuroprotective we have isolated APP binding proteins and identified the amyloid precursor-like protein 2 (APLP2) molecule as a strong candidate for the APP-neuroprotective receptor. This grant will investigate the interaction between APP and APLP2 as a novel neuroprotective pathway in TBI.
Understanding The Contribution Of Iron In Traumatic Brain Injury
Funder
National Health and Medical Research Council
Funding Amount
$601,263.00
Summary
Our group has discovered a novel role of amyloid precursor protein (APP) in cellular iron balance similar to another protein called ceruloplasmin (CP). Both, prevalently found in the brain, convert a damaging iron variety into the safer form. Disruption in either protein leads to cell death. We aim to establish how failure in APP and CP response may be detrimental to traumatic brain injury recovery. Understanding the iron role of APP and CP will lead to therapeutics to counter traumatic injury.
Preclinical Evaluation Of The Novel Therapeutic Compound APP96-110 In An Ovine Model Of Traumatic Brain Injury
Funder
National Health and Medical Research Council
Funding Amount
$874,734.00
Summary
Traumatic brain injury (TBI) is a significant cause of death and disability, and yet there are currently no effective treatments to improve outcome following such an insult. Our laboratory has developed a novel therapeutic compound, by identifying an endogenous neuroprotective molecule, in the amyloid precursor protein and then identifying the active site and modifying it to improve its efficacy. We will be testing this compound in our sheep model of TBI.
Exploring Scanning Ultrasound (SUS), A Novel Method To Treat And Prevent Neurodegenerative Disease
Funder
National Health and Medical Research Council
Funding Amount
$765,708.00
Summary
We developed a novel scanning ultrasound (SUS) protocol that clears toxic protein aggregates and restores memory function in mouse models of Alzheimer's disease (AD), without the need for therapeutic agents. Here we aim to determine whether SUS has preventative potential, whether there are synergistic effects, and whether a therapeutic antibody combined with SUS leads to an enhanced therapeutic outcome. Together this will guide the development of an ultrasound therapy in AD patients.
Traumatic Brain Injury, Post Traumatic Stress Disorder And The Risk Of Neurodegenerative Disease: A Study Of Tau And Beta-amyloid Accumulation, Brain Structure And Function Several Decades After Injury.
Funder
National Health and Medical Research Council
Funding Amount
$1,076,860.00
Summary
The study aims to better understand the association between traumatic brain injury (TBI), post traumatic stress disorder (PTSD) and dementia, specifically Alzheimer’s disease (AD) and chronic traumatic encephalopathy (CTE). The study will examine retired AFL players, road trauma victims and Vietnam veterans with advanced imaging using PET brain scans for the abnormal brain deposits typical of AD and CTE and assess the risk of later developing these diseases from head injury and PTSD.
Truncating Presenilin Mutations And Their Effects On Gamma-secretase Activity, Tau And Beta-catenin
Funder
National Health and Medical Research Council
Funding Amount
$414,005.00
Summary
Alzheimer's disease (AD) and cancer are increasingly important both in terms of human suffering and the burden of care it imposes on society and the economy. Sporadic (non-inherited) AD is the most common form of dementia but is poorly understood. The PRESENILIN genes, PSEN1 and PSEN2, are the major sites for mutations causing inherited AD and are also implicated in cancer. Using the zebrafish embryo model we have discovered that, contrary to current thought, mutations that truncate presenilin p ....Alzheimer's disease (AD) and cancer are increasingly important both in terms of human suffering and the burden of care it imposes on society and the economy. Sporadic (non-inherited) AD is the most common form of dementia but is poorly understood. The PRESENILIN genes, PSEN1 and PSEN2, are the major sites for mutations causing inherited AD and are also implicated in cancer. Using the zebrafish embryo model we have discovered that, contrary to current thought, mutations that truncate presenilin proteins potently suppress normal presenilin activity. (They are so called, dominant negatives). This means that they are lethal for embryo development and explains why such mutations have never been found in inherited AD. Notably, this discovery could only be made using a subtle form of gene manipulation that is possible in zebrafish embryos. Our work has also established the first assay for the non-apoptotic (non-cell death) function of PSEN2 and has shown that PSEN2 activity is inhibited by truncated PSEN1. This is the first indication of possible interaction between PSEN1 and PSEN2 proteins at normal physiological expression levels. Loss of presenilin activity promotes cancer. Truncated presenilin proteins could be produced by errors in gene transcription (aberrant transcript splicing) common in cancerous cells. This suggests that truncated, dominant negative forms of presenilin produced through aberrant splicing (or mutation in precancerous cells) might be common in tumour formation. The proposed research will define the region of PSEN1 in which truncation leads to dominant negative activity. This will allow further examination of the role of presenilins in the cell signalling pathways involved in AD and cancer. We will also investigate the role that age-related truncation of presenilins in human cells can play in the formation of sporadic AD. This may reveal a common molecular link between the inherited and sporadic forms of this disease.Read moreRead less